This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Müller, M. Articles by Blöchl-Daum, B. Search for Related Content PubMed PubMed Citation Articles by Müller, M. Articles by Blöchl-Daum, B.

Interstitial Methotrexate Kinetics in Primary Breast Cancer Lesions

Departments of Clinical Pharmacology [M. M., M. B., J. B., H. G. E., B. B-D.], Clinical and Laboratory Diagnosis [R. S.], and Internal Medicine I, Division of Oncology [R. M. M., G. G. S., B. S.], Vienna University School of Medicine, A-1090 Vienna, Austria

The transfer of cytotoxic agents across the tumor endothelium into the interstitial tumor space is considered a critical step in clinical resistance of solid tumors to antineoplastic chemotherapy. However, experimental data on drug transfer from the blood into the interstitium of solid tumors are scarce. Therefore, in this study, we used an innovative technique, in vivo microdialysis, for measuring interstitial tumor pharmacokinetics and plasma-to-tumor transfer rates of methotrexate (MTX) in breast cancer patients.

Microdialysis probes were inserted into the primary tumor and the periumbilical s.c. adipose layer of nine previously chemotherapy-naive breast cancer patients to monitor interstitial concentrations following i.v. administration of MTX (40 mg/m²) during a three-drug treatment regimen. Mean interstitial MTX load in breast tumors, expressed as area under curve (AUC), was 60 ± 20% (mean ± SE; coefficient of variation = 100%) of mean plasma MTX load. There was no correlation between plasma AUC and the AUC in the interstitial space of tumor tissue (P = 0.93). Not one of the parameters plasma, interstitial tumor load, and transfer rate of MTX to the interstitial space was associated with favorable clinical response.

In conclusion, plasma levels of MTX are not predictive of intratumor levels. There is a high interindividual variability in transendothelial MTX transfer. Under the present conditions, access of MTX to the interstitial space is not a rate-limiting step for clinical response to chemotherapy.

¹ To whom requests for reprints should be addressed, at Vienna University School of Medicine, AKH, Section of Clinical Pharmacokinetics, Department of Clinical Pharmacology, Währinger Gürtel 18–20, A-1090 Vienna, Austria. Phone: 43-1-40400-2981; Fax: 43-1-40400-2998; E-mail: markus.mueller@univie.ac.at.

Received 2/ 2/98. Accepted 5/29/98.

This article has been cited by other articles:

				K. Pietras, A. Östman, M. Sjöquist, E. Buchdunger, R. K. Reed, C.-H. Heldin, and K. Rubin Inhibition of Platelet-derived Growth Factor Receptors Reduces Interstitial Hypertension and Increases Transcapillary Transport in Tumors Cancer Res., April 1, 2001; 61(7): 2929 - 2934. [Abstract] [Full Text]